Can You Get Pregnant Taking Ozempic

Last reviewed: May 14, 2026

Last updated: May 14, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Yes, you can become pregnant while taking GLP-1 medications like semaglutide, but current evidence recommends discontinuing these medications before attempting conception. Regulatory guidance and clinical practice recommend stopping GLP-1 agonists at least two months before planned pregnancy to allow adequate washout.

If you're of reproductive age and considering GLP-1 treatment, understanding the evidence around pregnancy planning is crucial. PlexusDx supports precision wellness by helping you evaluate your individual health profile alongside clinical guidelines, enabling more informed conversations with your healthcare provider about timing and safety.

Why GLP-1 Medications Require Pregnancy Planning Considerations

GLP-1 receptor agonists were developed primarily for type 2 diabetes and weight management in non-pregnant adults. Limited human pregnancy data exists for these medications, which is why regulatory bodies and medical societies recommend discontinuation before conception. Animal studies have shown some adverse effects at high doses, though relevance to humans remains uncertain.

During pregnancy, maternal metabolism changes significantly, and fetal development depends on precise glucose regulation and nutrient balance. GLP-1 medications slow gastric emptying and reduce appetite, changes that may interfere with adequate maternal and fetal nutrition during the critical nine-month development window. This physiological concern drives conservative clinical guidance.

Current Clinical Evidence and Regulatory Guidance on GLP-1 Use and Pregnancy

FDA labeling for semaglutide, tirzepatide, and other GLP-1 agonists does not recommend use during pregnancy. Major medical organizations including the American College of Obstetricians and Gynecologists emphasize that these medications should be discontinued before conception attempts. Most clinicians recommend a two-month washout period to ensure medication clearance.

Recent real-world data from pregnancy registries shows outcomes in women who became pregnant while on GLP-1 medications, though sample sizes remain small. These observational studies have not identified catastrophic adverse outcomes, but evidence gaps persist. Rigorous prospective trials in pregnant populations are unlikely due to ethical constraints, leaving clinical recommendations based on precaution rather than definitive safety data.

Consideration	Current Evidence or Guidance
FDA Pregnancy Category	Not assigned; not recommended in pregnancy per labeling
Recommended Discontinuation Timing	Two months before planned conception
Mechanism of Concern	Limited human data; animal studies show dose-dependent effects
Metabolic Impact During Pregnancy	May reduce nutrient absorption and maternal-fetal glucose regulation
Real-World Pregnancy Data Available	Limited; mostly observational case reports and small registries
Guideline Source	ACOG, ADA, and medication manufacturers

Managing Weight and Metabolism During Pregnancy Planning and Conception

Stopping GLP-1 medications does not mean weight management stops during pregnancy planning. Evidence supports gradual lifestyle modifications including structured physical activity, protein-balanced nutrition, and behavioral counseling as sustainable alternatives. Many patients stabilize their weight in the months after GLP-1 discontinuation, particularly if they maintain dietary and activity patterns adopted during treatment.

Pregnancy itself brings metabolic changes that can affect weight trajectory. Early pregnancy often includes nausea and appetite shifts, while later pregnancy involves expected weight gain for fetal development. Your healthcare provider can help establish realistic expectations and monitor metabolic health markers throughout conception planning and pregnancy.

Who Should Consider GLP-1 Treatment if Pregnancy is Possible

Women of reproductive age seeking GLP-1 treatment should have an explicit conversation with their healthcare provider about pregnancy timing and intentions. If pregnancy is planned within 12 months, your provider may recommend alternative or delayed treatment strategies. If pregnancy is not planned, reliable contraception alongside GLP-1 therapy is a reasonable approach for eligible patients.

Certain patients benefit most from GLP-1 treatment despite reproductive considerations: those with type 2 diabetes requiring glucose control, patients with significant metabolic disease, or individuals for whom weight management provides substantial health benefits. Shared decision-making with your provider should weigh immediate health needs against reproductive timeline, ensuring safe care regardless of your choice.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context around your individual metabolic predispositions in GLP-1 receptor pathways and glucose regulation genes. Understanding your genetic profile in genes like GLP1R rs6923761 and FTO rs9939609 can support a more nuanced conversation with your provider about whether GLP-1 treatment aligns with your metabolic phenotype, particularly when pregnancy planning is a consideration.

The genetic test reveals predispositions in peptide response pathways, but it does not predict exact medication response or pregnancy outcomes. Genetic variants associated with GLP-1 receptor function and weight regulation can help contextualize your baseline metabolic risk, but they do not determine whether you can or should become pregnant on these medications. Test results should always be interpreted with a qualified healthcare provider.

If you're considering GLP-1 treatment and planning pregnancy within 12-24 months, combining your genetic insights with clinical evidence about discontinuation timing can support a more informed conversation with your provider about treatment initiation, duration, and pregnancy transition planning.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is it safe to become pregnant if I accidentally conceived while taking semaglutide?

If you learn you are pregnant while taking GLP-1 medication, contact your provider immediately. Most real-world cases have been monitored without reported major adverse outcomes, but your provider will want to assess your individual situation and recommend next steps for safe pregnancy management.

How long should I wait after stopping GLP-1 medication before trying to conceive?

Current guidance recommends discontinuing GLP-1 agonists two months before planned conception to allow adequate medication washout. Your provider may recommend additional time based on your specific medication, dose, and health status. Timing varies by individual circumstance.

Can I use compounded semaglutide or tirzepatide if I'm planning pregnancy?

Compounded GLP-1 medications from 503A pharmacies like those offered by PlexusDx should be discontinued with the same timeline and medical supervision as brand medications before conception. The compounding source does not change pregnancy safety considerations or discontinuation recommendations.

What happens to my weight after I stop GLP-1 treatment to prepare for pregnancy?

Weight often increases after GLP-1 discontinuation, though the magnitude varies widely. Many patients maintain significant benefit from lifestyle changes learned during treatment. Your provider can help manage expectations and support metabolic health during the pregnancy planning phase through nutrition and activity counseling.

Does the Precision Peptide Genetic Test predict how my body will handle pregnancy after GLP-1 treatment?

The Precision Peptide Genetic Test reveals predispositions in GLP-1 receptor and metabolic pathways, but does not predict pregnancy outcomes or your body's recovery after GLP-1 discontinuation. Genetic insights can contextualize your metabolic profile alongside clinical evidence to support planning conversations with your provider.